In addition to molecular targeting, Li et al. combined engineered OMVs with ICB in CRC therapy and obtained OMV-PD1 40 (Figure 3E-F) by fusing the PD-1 coding region with the ClyA coding region of E. coli. Here, PDCD1 is linked to colorectal carcinoma.